N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Sponsor: Peking University People's Hospital • ClinicalTrials.gov ID: NCT06468215

Registry updated: 2026-08-21
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Interventions

  • Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d. (Drug)
    Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.

Eligibility criteria

Inclusion Criteria: * Endometrioid adenocarcinoma G2, diagnosis by pathological. * The lesion is limited to the endometrium. * FIGO (2009) staging is IA. * Age less than 45. * Strongly request to preserve fertility. * Sign informed consent. Exclusion Criteria: * The tumor has invaded the muscle layer. * FIGO (2009) stage IB or higher. * Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer * There are malignant tumors in other systems. * Have contraindications for conservative treatment or drug use. * Have been judged by the researcher to be unsuitable for childbearing.

Conditions

Carcinoma, Endometrioid Fertility Preservation

Locations

  • Peking University People's Hospital — Beijing, Beijing Municipality, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record